Qnovia Secures Worldwide Exclusive License to Novel Antimicrobial Peptide from the University of Virginia

New therapeutic candidate offers potential to break the cycle driving antibiotic-resistant infections IRVINE, Calif., July 29, 2026 /PRNewswire/ -- Qnovia, Inc., a clinical-stage pharmaceutical company, today announced it has secured a worldwide exclusive license to an innovative...